{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.5","value":"789"},{"groupId":"OG001","spread":"30.7","value":"2390"},{"groupId":"OG002","spread":"27.3","value":"3090"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in phase 1 and phase 2 received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on day 1 cycle 1.","id":"OG000","title":"Carfilzomib 20 mg/m²"},{"description":"Participants in phase 1 and phase 2 received carfilzomib 70 mg/m² administered by intravenous (IV) infusion from day 8 cycle 1 onwards.","id":"OG001","title":"Carfilzomib 70 mg/m²"},{"description":"Participants in phase 1 received carfilzomib 88 mg/m² administered by intravenous (IV) infusion from day 8 cycle 1 onwards.","id":"OG002","title":"Carfilzomib 88 mg/m²"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analyses were conducted for participants assigned to cohorts 3 and 4 in phase 1 (70 and 88 mg/m² carfilzomib) and a subset of participants in phase 2; only participants for whom PK parameters could be calculated were included in the analyses.","reportingStatus":"POSTED","timeFrame":"Day 1 cycle 1 (20 mg/m² carfilzomib), cycle 1 day 15 (phase 1 70 and 88 mg/m² carfilzomib), and cycle 2 day 15 (phase 2 70 mg/m² carfilzomib) from predose to 4 hours after the end of the infusion.","title":"Maximum Plasma Concentration of Carfilzomib","type":"SECONDARY","unitOfMeasure":"ng/mL"}